Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer

Objectives: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment. Methods: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB...

Descripción completa

Detalles Bibliográficos
Autores: Pérez-Regadera Gómez, José Fermín, Sánchez-Muñoz, Alfonso, De-la-Cruz, Javier, Ballestín Carcavilla, Claudio, Lora Pablos, David, García-Martín, Rosa, Alonso-Carrión, Lorenzo, Mendiola Fernández, Dionisio César, Lanzós González, Eduardo
Tipo de recurso: artículo
Fecha de publicación:2010
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/116117
Acceso en línea:https://hdl.handle.net/20.500.14352/116117
Access Level:acceso abierto
Palabra clave:615.849.1
c-erb-B2 status
Disease-free survival
Local relapse rate
Advanced cervical cancer
Chemoradiotherapy
Oncología
3201.12 Radioterapia
3201.01 Oncología
id ES_5e66376faa30c80d7e88d0d867bb3d21
oai_identifier_str oai:docta.ucm.es:20.500.14352/116117
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical CancerPérez-Regadera Gómez, José FermínSánchez-Muñoz, AlfonsoDe-la-Cruz, JavierBallestín Carcavilla, ClaudioLora Pablos, DavidGarcía-Martín, RosaAlonso-Carrión, LorenzoMendiola Fernández, Dionisio CésarLanzós González, Eduardo615.849.1c-erb-B2 statusDisease-free survivalLocal relapse rateAdvanced cervical cancerChemoradiotherapyOncología3201.12 Radioterapia3201.01 OncologíaObjectives: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment. Methods: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark). Only c-erb-B2+++ biopsies were considered positive. All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously. Results: A total of 32 (23.5%) biopsies were considered c-erb-B2-positive. Three-year and 5-year DFS were 61% and 58% for c-erb-B2-negative patients and 36% and 36% for c-erB2-positive patients, respectively (P = 0.02). Patients were stratified in 4 groups according to their c-erb-B2 status and whether they received cisplatin. The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014). Conclusions: c-erb-B2 overexpression may imply a poor prognosis for patients with advanced CC. Treatment with cisplatin-based radiochemotherapy improved outcome in these patients.BMJ Publishing GroupUniversidad Complutense de Madrid20102010-01-0120102010-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/116117reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1161172026-06-02T12:44:21Z
dc.title.none.fl_str_mv Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
title Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
spellingShingle Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
Pérez-Regadera Gómez, José Fermín
615.849.1
c-erb-B2 status
Disease-free survival
Local relapse rate
Advanced cervical cancer
Chemoradiotherapy
Oncología
3201.12 Radioterapia
3201.01 Oncología
title_short Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
title_full Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
title_fullStr Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
title_full_unstemmed Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
title_sort Cisplatin-Based Radiochemotherapy Improves the Negative Prognosis of c-erbB-2 Overexpressing Advanced Cervical Cancer
dc.creator.none.fl_str_mv Pérez-Regadera Gómez, José Fermín
Sánchez-Muñoz, Alfonso
De-la-Cruz, Javier
Ballestín Carcavilla, Claudio
Lora Pablos, David
García-Martín, Rosa
Alonso-Carrión, Lorenzo
Mendiola Fernández, Dionisio César
Lanzós González, Eduardo
author Pérez-Regadera Gómez, José Fermín
author_facet Pérez-Regadera Gómez, José Fermín
Sánchez-Muñoz, Alfonso
De-la-Cruz, Javier
Ballestín Carcavilla, Claudio
Lora Pablos, David
García-Martín, Rosa
Alonso-Carrión, Lorenzo
Mendiola Fernández, Dionisio César
Lanzós González, Eduardo
author_role author
author2 Sánchez-Muñoz, Alfonso
De-la-Cruz, Javier
Ballestín Carcavilla, Claudio
Lora Pablos, David
García-Martín, Rosa
Alonso-Carrión, Lorenzo
Mendiola Fernández, Dionisio César
Lanzós González, Eduardo
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv 615.849.1
c-erb-B2 status
Disease-free survival
Local relapse rate
Advanced cervical cancer
Chemoradiotherapy
Oncología
3201.12 Radioterapia
3201.01 Oncología
topic 615.849.1
c-erb-B2 status
Disease-free survival
Local relapse rate
Advanced cervical cancer
Chemoradiotherapy
Oncología
3201.12 Radioterapia
3201.01 Oncología
description Objectives: To determine the impact of c-erb-B2 overexpression on disease-free survival (DFS) and local relapse in patients with advanced cervical cancer (CC) receiving concurrent chemoradiotherapy treatment. Methods: A total of 136 patients with advanced CC (FIGO stage: IB2-IIA [12]; IIB [34]; IIIB [71]; IVA [19]; including both epidermoid [86] and adenocarcinoma [14]) were analyzed to determine c-erb-B2 levels by immunohistochemistry (c-erb-B2 antibody; Dako, Glostrup, Denmark). Only c-erb-B2+++ biopsies were considered positive. All patients received pelvic radiotherapy, brachytherapy, and concurrent chemotherapy with 2 different regimens: 48 patients were treated with tegafur (800 mg/d orally) and 88 with tegafur (same doses) plus 5 cycles of weekly cisplatin 40 mg/m/wk intravenously. Results: A total of 32 (23.5%) biopsies were considered c-erb-B2-positive. Three-year and 5-year DFS were 61% and 58% for c-erb-B2-negative patients and 36% and 36% for c-erB2-positive patients, respectively (P = 0.02). Patients were stratified in 4 groups according to their c-erb-B2 status and whether they received cisplatin. The group of patients with c-erb-B2 overexpression that did not receive platinum treatment had a higher rate of pelvic relapse (P < 0.0001), associated with a decreased DFS (P = 0.0014). Conclusions: c-erb-B2 overexpression may imply a poor prognosis for patients with advanced CC. Treatment with cisplatin-based radiochemotherapy improved outcome in these patients.
publishDate 2010
dc.date.none.fl_str_mv 2010
2010-01-01
2010
2010-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/116117
url https://hdl.handle.net/20.500.14352/116117
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409113757188096
score 15.811543

Similares en LA Referencia